Revolution Medicines Inc (RVMD) - Net Assets
Based on the latest financial reports, Revolution Medicines Inc (RVMD) has net assets worth $1.50 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.25 Billion) and total liabilities ($753.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Revolution Medicines Inc (RVMD) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.50 Billion |
| % of Total Assets | 66.55% |
| Annual Growth Rate | 108.71% |
| 5-Year Change | 170.72% |
| 10-Year Change | N/A |
| Growth Volatility | 654.55 |
Revolution Medicines Inc - Net Assets Trend (2017–2025)
This chart illustrates how Revolution Medicines Inc's net assets have evolved over time, based on quarterly financial data. See Revolution Medicines Inc (RVMD) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Revolution Medicines Inc (2017–2025)
The table below shows the annual net assets of Revolution Medicines Inc from 2017 to 2025. For live valuation and market cap data, see Revolution Medicines Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.63 Billion | -27.98% |
| 2024-12-31 | $2.27 Billion | +24.04% |
| 2023-12-31 | $1.83 Billion | +166.52% |
| 2022-12-31 | $685.19 Million | +13.71% |
| 2021-12-31 | $602.57 Million | +26.94% |
| 2020-12-31 | $474.68 Million | +211.19% |
| 2019-12-31 | $152.53 Million | +57.81% |
| 2018-12-31 | $96.66 Million | +2033.28% |
| 2017-12-31 | $4.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revolution Medicines Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 280116900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.00% |
| Other Comprehensive Income | $3.24 Million | 0.20% |
| Other Components | $4.50 Billion | 275.68% |
| Total Equity | $1.63 Billion | 100.00% |
Revolution Medicines Inc Competitors by Market Cap
The table below lists competitors of Revolution Medicines Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KB Financial Group Inc
F:KBIA
|
$31.74 Billion |
|
Honda Motor Co Ltd ADR
NYSE:HMC
|
$31.76 Billion |
|
SUMITOMO CORP. SP. ADR 1
F:SUMB
|
$31.83 Billion |
|
FUJITSU LTD. ADR 5/1
F:FUJA
|
$31.87 Billion |
|
Baidu Inc
F:B1C
|
$31.70 Billion |
|
Nan Ya Plastics Corp
TW:1303
|
$31.61 Billion |
|
Gold Fields Ltd
JSE:GFI
|
$31.60 Billion |
|
VOLKSWAGEN ADR 1/10/O.N.
F:VOWA
|
$31.57 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revolution Medicines Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,265,204,000 to 1,631,297,000, a change of -633,907,000 (-28.0%).
- Net loss of 1,131,301,000 reduced equity.
- Share repurchases of 8,036,000 reduced equity.
- New share issuances of 347,915,000 increased equity.
- Other comprehensive income increased equity by 1,916,000.
- Other factors increased equity by 155,599,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.13 Billion | -69.35% |
| Share Repurchases | $8.04 Million | -0.49% |
| Share Issuances | $347.92 Million | +21.33% |
| Other Comprehensive Income | $1.92 Million | +0.12% |
| Other Changes | $155.60 Million | +9.54% |
| Total Change | $- | -27.98% |
Book Value vs Market Value Analysis
This analysis compares Revolution Medicines Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 18.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1270.00x to 18.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.12 | $157.77 | x |
| 2018-12-31 | $2.65 | $157.77 | x |
| 2019-12-31 | $4.18 | $157.77 | x |
| 2020-12-31 | $7.13 | $157.77 | x |
| 2021-12-31 | $8.28 | $157.77 | x |
| 2022-12-31 | $8.50 | $157.77 | x |
| 2023-12-31 | $16.14 | $157.77 | x |
| 2024-12-31 | $13.50 | $157.77 | x |
| 2025-12-31 | $8.58 | $157.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revolution Medicines Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.44x
- Recent ROE (-69.35%) is above the historical average (-107.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -686.98% | 0.00% | 0.00x | 3.33x | $-31.58 Million |
| 2018 | -43.23% | -207.24% | 0.12x | 1.76x | $-51.45 Million |
| 2019 | -31.25% | -95.25% | 0.23x | 1.45x | $-62.92 Million |
| 2020 | -22.79% | -251.63% | 0.08x | 1.20x | $-155.63 Million |
| 2021 | -31.05% | -636.58% | 0.04x | 1.22x | $-247.35 Million |
| 2022 | -36.30% | -702.95% | 0.04x | 1.18x | $-317.22 Million |
| 2023 | -23.89% | -3768.28% | 0.01x | 1.13x | $-618.99 Million |
| 2024 | -26.49% | 0.00% | 0.00x | 1.13x | $-826.61 Million |
| 2025 | -69.35% | 0.00% | 0.00x | 1.44x | $-1.29 Billion |
Industry Comparison
This section compares Revolution Medicines Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revolution Medicines Inc (RVMD) | $1.50 Billion | -686.98% | 0.50x | $31.73 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more